MAA
RVNC

Managed Account Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Managed Account Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-258
Closed -$4K – 3074
2014
Q4 		$4K Sell
258
-724
-74% -$12.6K ﹤0.01% 2670
2014
Q3 		$19K Buy
982
+322
+49% +$8.39K ﹤0.01% 2543
2014
Q2 		$22K Buy
660
+498
+307% +$15.6K ﹤0.01% 2494
2014
Q1 		$5K Buy
+162
New +$5.06K ﹤0.01% 2577

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Managed Account Advisors's RVNC Position: Q1 2015 in Review

Managed Account Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2015, closing a stake of 258 shares — an estimated $4K sold.

Managed Account Advisors first reported a position in RVNC in Q1 2014 and held it in 4 quarters. The position peaked at $22K in Q2 2014. 70 funds tracked by Wall St. Rank hold RVNC as of Q1 2015.

  • Managed Account Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Managed Account Advisors sold 258 Revance Therapeutics, Inc. shares in Q1 2015, an estimated $4K.
  • Managed Account Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • Managed Account Advisors's Revance Therapeutics, Inc. position peaked at $22K in Q2 2014.
  • 70 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2015.

Based on Managed Account Advisors's 13F filing for Q1 2015, filed 15 May 2015.